Igenica: Pierre Fabre Acquires Igenica Immuno-Oncology Assets

Pierre Fabre said today it has agreed to acquire "several" cancer immunotherapies from Igenica Biotherapeutics for an undisclosed price, in a deal designed to strengthen the buyer's oncology pipeline. Pierre Fabre also did not disclose how many immuno-oncology candidates it acquired-but did say the most advanced of those is a preclinical asset "expected to be administered to patients in the coming 2 to 3 years." The deal includes candidates designed to target immune checkpoints that may reverse the resistance to existing immunotherapies, as well as a series of early discovery targets. "This new deal reinforces our position to participate in the revolution of targeted biotherapies and reinforce our commitment to bring substantial value to patients," Frédéric Duchesne, Pharmaceutical Division CEO at Pierre Fabre, said in a statement. Financial terms were not disclosed. Laurent Audoly, Ph.D., head of Pierre Fabre Pharmaceuticals R&D, added that the deal ...